伊奈利珠单抗 T76713

Product Introduction
Bioactivity


英文名: Inebilizumab

描述: Inebilizumab 是一种人源化抗 CD19 单克隆抗体，对 B 细胞具有增强的抗体依赖细胞介导的细胞毒性。Inebilizumab 可用于治疗多发性硬化和视神经脊髓炎等一些与 CD19的B细胞相关的一系列自身免疫性疾病。

体外活性: Derived from the mouse anti-human mAb HB12b, Inebilizumab had already shown impressive activity in depleting B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg)[1].Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells[1].Inebilizumab demonstrates equal or better activity than Rituximab in depleting human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells[1].

体内活性: In vivo, Inebilizumab (MEDI-551) (i.v.; once; 0-10 mg/kg) depletes B cells from blood and spleen by mouse macrophages, and it induces phagocytosis of murine B cells ex vivo[2].

存储条件: store at low temperaturestore at -20°C

关键字: VIB 0551 | Inebilizumab | MT0551 | MEDI551 | MT 0551 | MEDI-551 | VIB0551

伊奈利珠单抗 T76713信息由TargetMol中国为您提供，如您想了解更多关于伊奈利珠单抗 T76713报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途